CNBC's Fast Money team takes a look at five technology stocks that are set to fly higher.» Read More
Jim Cramer speaks to the CEO of Target on how he managed to turn around the business, and its new collaboration with Lilly Pulitzer.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
While new economic data painted a mixed picture on the economy, two economists believe the economy should continue to recover.
Companies finally may be getting the message that it's better to invest in the future.
Check out the companies making headlines after the bell Monday: Netapp, PVH, Old Dominion Freight & more.
Singularity-CNBC conference kicks off
One influential economist is saying investors need not worry about current valuations, and he has a 45-year chart to prove his point.
Top technician Carter Worth says Apple and biotech look "married." He explains why they are the must-own names in the market right now.
"Our 40 percent 'grey sky' scenario for European equity returns to end-2016 is based on three key factors," according to Citi.
Technical analyst Craig Johnson shows why the U.S. dollar could be set to shoot higher.
The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.
Wall Street’s been soaking in red, but Jim Cramer has one signal to watch for that could point to another run in the "Mad Money" review.
Some of the names on the move ahead of the open.
Delphi Management founder Scott Black says the S&P 500 is already "fully valued," while small- and mid-cap companies are "overvalued."
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
Legendary trader Laszlo Birinyi sees all the bearish talk from his peers and the media and takes the opposite view.
Markets face a barrage of potential catalysts as the month of June begins, a traditional period of stock market weakness.